{"url_path":"/sec/aeon/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1837607/0001837607-26-000042-index.html","accession_number":"0001837607-26-000042","cik":"0001837607","ticker":"AEON","issuer_name":"AEON Biopharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1837607/0001837607-26-000042-index.html","primary_entity_key":"0001837607","primary_entity_name":"AEON Biopharma, Inc."},"word_count":930,"has_tables":true,"body_markdown":"**Item 6. Exhibits**\n\nSee Exhibit Index.\n\n​\n\n42\n\n[Table of Contents](#TOC)\n\n**EXHIBIT INDEX**\n\n**Exhibit********No.**\n\n**  ​ ​ ​**\n\n**Description**\n\n2.1*\n\n​\n\n[Business Combination Agreement, dated as of December 12, 2022, by and among Priveterra Acquisition Corp., Priveterra Merger Sub, Inc. and AEON Biopharma, Inc. (incorporated by reference to Exhibit 2.1 to the Form 8-K filed by Priveterra Acquisition Corp. with the SEC on December 13, 2022)](https://www.sec.gov/Archives/edgar/data/1837607/000110465922126489/tm2232428d1_ex2-1.htm)\n\n2.1(a)*\n\n​\n\n[Amendment No. 1 to Business Combination Agreement, dated as of April 27, 2023, by and among Priveterra Acquisition Corp., AEON Biopharma, Inc. and Priveterra Merger Sub, Inc. (incorporated by reference to Exhibit 2.1 to the Form 8-K filed by Priveterra Acquisition Corp. with the SEC on May 1, 2023)](https://www.sec.gov/Archives/edgar/data/1837607/000110465923053387/tm2314221d1_ex2-1.htm)\n\n3.1\n\n​\n\n[Third Amended and Restated Certificate of Incorporation of AEON Biopharma, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed by the Company with the SEC on July 27, 2023)](https://www.sec.gov/Archives/edgar/data/1837607/000110465923084851/tm2314948d1_ex3-1.htm)\n\n3.1.1\n\n​\n\n[Certificate of Amendment of Third Amended and Restated Certificate of Incorporation of AEON Biopharma, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed by the Company with the SEC on February 24, 2025)](https://www.sec.gov/Archives/edgar/data/1837607/000183760725000013/aeon-20250224xex3d1.htm)\n\n3.2\n\n​\n\n[Amended and Restated Bylaws of AEON Biopharma, Inc. (incorporated by reference to Exhibit 3.2 to the Form 8-K filed by the Company with the SEC on July 27, 2023)](https://www.sec.gov/Archives/edgar/data/1837607/000110465923084851/tm2314948d1_ex3-2.htm)\n\n3.2.1\n\n​\n\n[Amendment to Amended and Restated Bylaws of AEON Biopharma, Inc. (incorporated by reference to Exhibit 3.1 to Form 8-K filed by the Company with the SEC on December 20, 2024)](https://www.sec.gov/Archives/edgar/data/1837607/000110465924130805/tm2431750d1_ex3-1.htm)\n\n4.1\n\n​\n\n[Warrant Agreement, dated as of February 8, 2021, by and between Priveterra Acquisition Corp. and Continental Stock Transfer & Trust Company (incorporated by reference to Exhibit 4.1 to the Form 10-K filed by Priveterra Acquisition Corp. with the SEC on March 28, 2022)](https://www.sec.gov/Archives/edgar/data/1837607/000110465921021987/tm2039147d12_ex4-1.htm)\n\n4.2\n\n​\n\n[Specimen Warrant Certificate (incorporated by reference to Exhibit 4.2 to the Form 10-K filed by Priveterra Acquisition Corp. with the SEC on March 29, 2024)](https://www.sec.gov/Archives/edgar/data/1837607/000110465921021987/tm2039147d12_ex4-1.htm)\n\n4.3\n\n​\n\n[Senior Secured Convertible Note, dated as of March 24, 2024, by and among AEON Biopharma, Inc., Daewoong Pharmaceutical Co., LTD. and AEON Biopharma Sub, Inc. (incorporated by reference to Exhibit 4.1 to the Form 8-K filed by the Company with the SEC on March 28, 2024)](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001837607/000183760724000008/aeon-20240324xex4d1.htm)\n\n4.4\n\n​\n\n[Senior Secured Convertible Note, dated as of April 12, 2024, by and among AEON Biopharma, Inc., Daewoong Pharmaceutical Co., LTD. and AEON Biopharma Sub, Inc. (incorporated by reference to Exhibit 4.1 to the Form 8-K filed by the Company with the SEC on April 17, 2024)](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001837607/000183760724000033/aeon-20240412xex4d1.htm)\n\n4.5\n\n​\n\n[Description of AEON Biopharma Inc.’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to Exhibit 4.5 to the Form 10-K filed by the Company with the SEC on August 12, 2024)](https://www.sec.gov/Archives/edgar/data/1837607/000110465924088355/tm2421402d1_ex4-5.htm)\n\n4.6\n\n​\n\n[Form of Series A Warrant (incorporated by reference to Exhibit 4.1 to the Form 10-K filed by the Company with the SEC on January 7, 2025)](https://www.sec.gov/Archives/edgar/data/1837607/000110465925001665/tm2432042d4_ex4-1.htm)\n\n4.7\n\n​\n\n[Form of Series B Warrant (incorporated by reference to Exhibit 4.2 to the Form 10-K filed by the Company with the SEC on January 7, 2025)](https://www.sec.gov/Archives/edgar/data/1837607/000110465925001665/tm2432042d4_ex4-2.htm)\n\n31.1†\n\n​\n\n[Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](aeon-20260331xex31d1.htm)\n\n31.2†\n\n​\n\n[Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](aeon-20260331xex31d2.htm)\n\n32.1#\n\n​\n\n[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](aeon-20260331xex32d1.htm)\n\n32.2#\n\n​\n\n[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](aeon-20260331xex32d2.htm)\n\n101.INS†\n\n​\n\nXBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document\n\n101.SCH†\n\n​\n\nXBRL Taxonomy Extension Schema Document\n\n101.CAL†\n\n​\n\nXBRL Taxonomy Extension Calculation Linkbase Document\n\n101.DEF†\n\n​\n\nXBRL Taxonomy Extension Definition Linkbase Document\n\n101.LAB†\n\n​\n\nXBRL Taxonomy Extension Label Linkbase Document\n\n101.PRE†\n\n​\n\nXBRL Taxonomy Extension Presentation Linkbase Document\n\n104†\n\n​\n\nCover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)\n\n†\n\nFiled herewith.\n\n*\n\nThe annexes, schedules, and certain exhibits to this Exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby agrees to furnish supplementally a copy of any omitted annex, schedule or exhibit to the SEC upon request.\n\n#\n\nThe certification attached as Exhibits 32.1 and 32.2 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the SEC and is not to be incorporated by reference into any filing of AEON Biopharma, Inc. under the Securities Act of\n\n43\n\n[Table of Contents](#TOC)\n\n1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.\n\n​\n\n​\n\n44\n\n[Table of Contents](#TOC)\n\n**SIGNATURES**\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\nDate: May 14, 2026\n\n​\n\n​\n\n​\n\n​\n\n**AEON BIOPHARMA, INC.**\n\n​\n\n​\n\n​\n\n​\n\nBy:\n\n/s/ Robert Bancroft\n\n​\n\nName:\n\nRobert Bancroft\n\n​\n\nTitle:\n\nPresident and Chief Executive Officer\n\n​\n\n​\n\n(Principal Executive Officer)\n\n​\n\n​\n\n​\n\n​\n\nBy:\n\n/s/ John Bencich\n\n​\n\nName:\n\nJohn Bencich\n\n​\n\nTitle:\n\nChief Financial Officer\n\n​\n\n​\n\n(Principal Financial Officer)\n\n​\n\n​\n\n​\n\n​\n\nBy:\n\n/s/ Jennifer Sy\n\n​\n\nName:\n\nJennifer Sy\n\n​\n\nTitle:\n\nChief Accounting Officer\n\n​\n\n​\n\n(Principal Accounting Officer)\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n45"}